4 Dicembre 2017 - Con il Premio, quest'anno alla sua I Edizione, la Fondazione intende valorizzare i ricercatori italiani che svolgono le migliori ricerche, cliniche o biologiche applicate, pubblicate o in corso di pubblicazione, su riviste scientifiche indicizzate.
June 6, 2015 - The next conference on Neurological Clinical Trials will be held in Milan the next June, 25. A focus on Huntington Disease will be presented by Prof Ferdinando Squitieri.
Our Scientific Director, Ferdinando Squitieri, as the author representing Italy.
A joint press release from the companies Prilenia and Ferrer announced today the publication in Nature Medicine, one of the world's leading peer-reviewed medical journals, of the results of the phase 3 Proof-HD study, coordinated in Italy by Prof.
This is the title of a study by the HD Unit of the IRCCS Casa Sollievo della Sofferenza in collaboration with the LIRH Foundation and Lancaster University - just published in the Journal of Huntington’s Disease.
When we think of a family affected by Huntington's disease, we often focus on the affected person or the primary caregiver. Yet, we rarely imagine the point of view of children who, even when they are not aware that the disease is present in their family, suffer and absorb the consequences.
Two studies recently published reveal significant new insights into the understanding of Huntington's disease. The studies were conducted by different research groups, but share conclusions that point in the same direction. Therefore, 2025 begins with a strong acceleration of knowledge about Huntington's disease.
HUNTINGTON: The mutation modifies its length over time within neurons, and it is now possible to detect signs of biological changes many years before the onset of symptoms.
by Ferdinando Squitieri, MD, PhD
Two studies recently published reveal significant new insights into the understanding of Huntington's disease. The studies were conducted by different research groups, but share conclusions that point in the same direction. Therefore, 2025 begins with a strong acceleration of knowledge about Huntington's disease.
LIRH Foundation is proud to participate in a prestigious and ambitious scientific and cultural project about prevention of neurodegenerative disorders, including Huntington's disease.
“Preserving the Brain: A Call to Action” - part of the Human Brains project promoted by Fondazione Prada in 2018 - aims to focus on the importance of prevention and early treatment of widespread and still incurable diseases, such as Alzheimer’s, Huntington’s, Parkinson’s, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis.
The full dossier was was sent to EMA by Prilenia at the end of July.
Last August 13, 2024, Lega Italiana Ricerca Huntington (LIRH) Umbria Association was officially born, on the initiative of a group of family members.
"Perugia, 13 August 2024 - LIRH Umbria was officially born today. It all started from the desire to help and support HD affected individuals and their families. With our personal experience, we want to be, in our territory, the guide that is missing among doctors, hospitals and bureaucracy. We want to be the thread that unites us with the LIRH Foundation and with prof. Ferdinando Squitieri, for years alongside families with Huntington's disease who, together with his staff, support all of us as a researcher and as a physician".
In a recent community letter sent out on January 26, Prilenia Therapeutics announced that people who took part in the PROOF-HD phase three trial will be able to take pridopidine, the experimental drug administered as part of this study, thanks to a expanded access/compassionate use program (EAP/CUP).
An important study has led to the development of a cognitive assessment tool that could help predict the severity of Huntington disease (HD) in those close to onset.
Huntington disease (HD) - a condition that affects one’s movement, cognition, and behavior—manifests fully in adulthood.
